Novo Nordisk Inks $600M Genetic Medicines Pact With Canadian Firm To Target Cardiometabolic Indications
Novo Nordisk Inks $600M Genetic Medicines Pact With Canadian Firm To Target Cardiometabolic Indications
Under the agreement, Novo Nordisk and NanoVation will collaborate on two lead programs to develop base-editing therapies for certain rare genetic diseases and up to five additional future targets for cardiometabolic and rare diseases.Wednesday, Canada-based NanoVation Therapeutics announced a multi-year partnership with Novo Nordisk A/S (NYSE:NVO) to advance the development of novel genetic medicines targeting cardiometabolic and rare diseases.
加拿大NanoVation Therapeutics週三宣佈與Novo Nordisk A/S（紐交所）達成多年合作伙伴關係，共同推進針對心代謝和罕見病的新型基因藥物的開發。
The partnership combines NanoVation Therapeutics' proprietary long-circulating lipid nanoparticle (lcLNP) technology for RNA delivery to cells outside the liver with Novo Nordisk's expertise in cardiometabolic and rare disease R&D and clinical translation.
該合作將NanoVation Therapeutics的專有長循環脂質納米粒（lcLNP）技術用於肝臟以外細胞的RNA遞送與Novo Nordisk在心代謝和罕見病研發及臨床轉化方面的專業知識相結合。
Also Read: Ozempic Maker Novo Nordisk Touts Encouraging Data From New Obesity Pill Showing Double Weight Loss Compared To Wegovy.
此外，Novo Nordisk重點品種Ozempic的製造商Novo Nordisk宣佈從新肥胖藥中獲得的鼓舞人心的數據，顯示其與Wegovy相比對減重的效果是兩倍。
Under the agreement, Novo Nordisk and NanoVation will collaborate on two lead programs to develop base-editing therapies for certain rare genetic diseases and up to five additional future targets for cardiometabolic and rare diseases.
根據協議，Novo Nordisk和NanoVation將合作開展兩個主要計劃，以開發用於某些罕見遺傳疾病的鹼基編輯療法，並且最多還會有五個其他未來的心代謝和罕見病靶向。
Novo Nordisk will receive a defined exclusive, worldwide license to use NanoVation's LNP technology for the two lead programs. NanoVation will receive research funding and is eligible to receive up to approximately $600 million in up-front cash, potential milestone payments, and tiered royalties on future product sales.
Novo Nordisk將獲得NanoVation的LNP技術在兩個主要計劃中的獨家全球許可。 NanoVation將獲得研究資金，並有資格獲得高達約60000萬美元的預付現金、潛在里程碑付款以及未來產品銷售的分階段版稅。
NanoVation has an extensive and continuously growing library of novel lipids and LNP compositions.
NanoVation擁有一個龐大且不斷增長的新型脂質和LNP組合物庫。
In preclinical studies, NanoVation's lcLNP technology has demonstrated the ability to deliver nucleic acids to various cell types beyond the liver with improved potency, safety, and stability compared to conventional systems.
在臨床前研究中，NanoVation的lcLNP技術已經證明了與傳統系統相比，在多種細胞類型中以提高的效力、安全性和穩定性遞送核酸的能力。
On Monday, Korro Bio Inc. (NASDAQ:KRRO) announced a collaboration with Novo Nordisk to advance the discovery and development of new genetic medicines. The initial target is cardiometabolic diseases.
週一，Korro Bio Inc.（納斯達克：KRRO）宣佈與Novo Nordisk合作推進新型遺傳藥物的發現和開發。初始目標是心代謝疾病。
The collaboration will focus on developing RNA editing product candidates for two undisclosed targets using Korro's proprietary platform.
該合作將專注於利用Korro的專有平台開發兩個未公開目標的RNA編輯產品候選人。
Korro is eligible to receive up to $530 million in upfront, development, and commercial milestone payments, in addition to tiered royalties and R&D funding.
Korro有資格獲得最高5300萬美元的預付款、開發款、商業里程碑支付，以及分層特許權和研發資金。
Korro will advance up to two programs through preclinical development, after which Novo Nordisk could further advance the programs through clinical studies.
Korro將通過臨床前發展推進最多兩個項目，之後諾和諾德可進一步推進臨床研究。
Price Action: NVO stock is up 0.62% at $132.82 at the last check on Wednesday.
價格行爲：在上週三的最後一次查證中，NVO股票上漲0.62%，收於132.82美元。
- AstraZeneca's Asthma Drug Gets FDA Approval For Rare Disease Of Blood Vessel Inflammation.
- 阿斯利康的哮喘藥物獲得FDA批准，用於罕見的血管炎症疾病。
Photo via Shutterstock
圖片來自shutterstock。
譯文內容由第三人軟體翻譯。